Synonyms: Hympavzi® | marstacimab-hncq
marstacimab is an approved drug (EMA & FDA (2024))
Compound class:
Antibody
Comment: Marstacimab (PF-06741086) is a monoclonal antibody that targets tissue factor pathway inhibitor (TFPI) [4]. The antibody blocks the inhibitory effect of TFPI on the FVIIa-TF complex interaction with coagulation factor Xa. This mechanism is proposed to increase coagulation activity of both the intrinsic and extrinsic coagulation pathways, for example in patients with severe haemophilia A or B.
|
Classification ![]() |
|
Compound class | Antibody |
Approved drug? | Yes. FDA (2024) | EMA (2024) |
International Nonproprietary Names ![]() |
|
INN number | INN |
10789 | marstacimab |
Synonyms ![]() |
Hympavzi® | marstacimab-hncq |
Database Links ![]() |
|
Specialist databases | |
IMGT/mAb-DB | 852 |
Other databases | |
GtoPdb PubChem SID | 496703373 |
Search PubMed clinical trials | marstacimab |
Search PubMed titles | marstacimab |
Search PubMed titles/abstracts | marstacimab |